Prostate cancer.
Schlegel
P N
PN
Cornell University Medical College, New York, New York.
D058891:5-alpha Reductase Inhibitors; D000368:Aged; D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D018572:Disease-Free Survival; D004967:Estrogens / Q000627:therapeutic use; D018120:Finasteride / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006801:Humans; D007986:Luteinizing Hormone / Q000037:antagonists & inhibitors / Q000378:metabolism; D008207:Lymphatic Metastasis; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D015995:Prevalence; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000150:complications; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D011878:Radiotherapy / Q000379:methods
D058891:5-alpha Reductase Inhibitors; D016588:Anticarcinogenic Agents; D004967:Estrogens; D007987:Gonadotropin-Releasing Hormone; D018120:Finasteride; D007986:Luteinizing Hormone; D017430:Prostate-Specific Antigen